{
    "nct_id": "NCT05329766",
    "official_title": "A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)",
    "inclusion_criteria": "* Participants with histologically confirmed diagnosis of locally advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma with life expectancy â‰¥3 months as assessed by the Investigator\n* Eastern cooperative oncology group (ECOG) Performance Score of 0-1\n* At least one measurable target lesion per RECIST v1.1.\n* Adequate organ and marrow function\n* Able to provide an archival tumor sample that is representative of the cancer under investigation and suitable for central PD-L1 testing\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational products hazardous\n* Only for Cohort A: Known Human Epidermal Growth Factor Receptor 2 (HER-2) positive tumor\n* Known untreated, symptomatic, or actively progressing central nervous system (brain) metastases. Participants with leptomeningeal metastases are excluded from enrollment.\n* Discontinued use of prior immune checkpoint therapy due to immune related adverse events; received prior treatment with an anti-TIGIT monoclonal antibody.\n* History of trauma or major surgery within 28 days prior to enrollment.\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}